Cannabis, 280E, and Delta 8: A Discussion of Tax Issues Unique to Selling Cannabis

Date December 9, 2021
Categories

Highlights from the December 9, 2021 webinar hosted by Christopher T. Marrie, CPA, CCIFP, Principal and National Director, HBK Cannabis Solutions.

• HBK Cannabis Solutions has been working with cannabis businesses throughout the United States and abroad since 2018. It is a dedicated, all-in group of professionals counseling clients as the industry has evolved and governments’ positions change or remain steadfast.

• The history of governance over the industry indicates that you need to consider all possibilities anytime there is a new aspect of the cannabis industry, as is the situation with Delta 8 sales.

• Cannabis exists in two species: hemp and marijuana

– The Farm Bill of 2018 distinguished the two as:

— Hemp is defined as less than 0.3 percent THC, not pschyo-active, but high in CBD. It falls under compliance with the Farm Bill and is completely legal

— If it doesn’t meet that criterion, it is considered a controlled substance. Delta 8 was excluded from the Farm Bill, and has been addressed differently by different branches of government.

• The Controlled Substances Act categorizes Schedule 1 substances as having high potential for abuse, no current accepted medical use, and lacking accepted safety for use under medical supervision.

• Delta 8 THC has been specifically listed by the Department of Justice (DOJ) as a Schedule 1 controlled substance.

• Tax implications:

– As taxpayers, any trade or business is allowed to deduct ordinary and necessary expenses to conduct business. But that is not the case for the cannabis industry. IRC Section 280E regarding trafficking in controlled substances, even if legal in a state, denies deductibility for tax purposes of all but direct costs of inventory. Applicability and enforcement have expanded over the years.

– 280E has a particularly severe negative impact on retailers due to their required investments in operations, including employees. A retailer could end up cash-flow negative but still with a substantial tax liability. The impact is more severe for S corporation pass-through businesses.

– Hemp in not covered by 280E if the business has implemented an official agricultural pilot program allowing cultivation of “industrial hemp” or any part of the cannabis plant with less than 0.3 percent THC in dry weight.

• The CDC received more than 600 reports of adverse reactions to Delta 8 in 2021.

• The Drug Enforcement Agency (DEA) has issued its opinion that Delta 8 is a Schedule 1 controlled substance. Some states are outlawing it and others are considering legislation to change their position. The DEA and DOJ positions will clearly dictate the level of enforcement by the IRS.

• In November 2021, the DEA clarified its position on Delta 8, acquiescing that Delta 8 is covered by the Farm Bill if you are compliant with all other aspects of the Bill. Derivatives of Hemp are also covered protected by the Farm Bill assuming they’re produced exclusively from cannabis materials. But for most Delta 8 products, CBD is extracted and put through a conversion process, a synthetic conversion, so you are not using exclusively cannabis material. As well, Delta 8 remains listed by the DOJ as a Schedule 1 controlled substance.

• IRS enforcement relative to Delta 8 has been very aggressive and highly antagonistic to the taxpayer. They are taking a rigid, hard-line position in enforcing this aspect of the tax code. They’ve been selective about who they take to court so as to ensure favorable rulings. We are not optimistic that the IRS will act in good faith interpreting the DEA position.

• The IRS has been under-funded in recent years, but there is $88 billion in IRS funding in the Build Back Better bill, $45 billion of which is dedicated to enforcement. We are confident that a big part of that enforcement will target cannabis businesses.

• If you’re selling Delta 8, first understand the ramifications, what the IRS might do, and be prepared for subsequent audits. Comply as much as possible with the 280E code as written and proactively segregate any aspects of your business at risk from the rest of your business. Understand what the potential tax liability and penalties might be in case there is enforcement.

• The greatest concern is for standalone retailers. Two types of businesses are selling Delta 8. One is a compliant CBD dealer now selling Delta 8 products; for them, adjustments from the IRS could be substantial. The impact could be more onerous on people in completely non-cannabis retail businesses, such as convenience stores, that have entered the Delta 8 space.

• If you’re going to continue selling Delta 8 products, we recommend that you segregate that from your other business. Our recommendations include:

– A different sets of books and insurance policies

– Different locations

– Separate management and employees

– Businesses that operate independently of each other

• Implement procedures, processes and controls that demonstrate you’ve made every effort to segregate the businesses.

• Legal sellers of CBD products must also segregate Delta 8 sales as much as possible to insulate themselves from the potential of a substantial adjustment in taxes for your entire business.

• Until there is more clarity on what is or isn’t Schedule 1, we will continue to operate in an area of confusion.

• Approach any new CBD products that come to market by being prepared for the worst.

Speak to one of our professionals about your organizational needs

"*" indicates required fields

hbkcpa.com needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.



IRS Denial of Certain Cannabis-Based Tax Deductions is Confirmed

Date January 25, 2019
In a United States Tax Court case1 decided November 29, 2018, the court reaffirmed the Internal Revenue Service’s disallowance of certain deductions for companies operating in the cannabis industry. Background Patients Mutual Assistance Collective Corporation d/b/a Harborside Health Center (HHC) is a California medical marijuana dispensary, operating four industry-related activities. HHC believed each of its activities was a unique trade or business. The activities are: Brand Development, Therapeutic Services, Sales of Products Containing No Marijuana, Sales of Marijuana and Products Containing Marijuana. Internal Revenue Code (“Code”) Section 280E (“280E”) states:

No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of Schedule I and Schedule II of the Controlled Substances Act) which is prohibited by Federal Law or the law of any state in which the trade or business is conducted.

Resolutions 1) 280E The Code allows a business to deduct all its “ordinary and necessary expenses paid or incurred during the taxable year in carrying on any trade or business.” However, as stated previously, Code Section 280E contains an exception disallowing expenses related to … “carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of Schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted.” HHC argued that “consists of” means an exhaustive list or in other words “Section 280E only applies to business that exclusively or solely traffic in controlled substances and not to those that also engage in other activities.” The IRS argued that a single business can have multiple activities and that 280E applies to an entire trade or business if any one of its activities is trafficking in a controlled substance.2 The Tax Court ruled “Following the most common usage of ‘consists of’, as HHC suggests, would indeed make Section 280E ineffective. If this section denies deductions only to businesses that exclusively traffic in controlled substances, then any street-level drug dealer could circumvent it by selling a single item that was not a controlled substance … This reading would edge us close to absurdity, which is another result our reading of a statute should avoid if possible.” 2) More Than One Trade or Business “An activity is a trade or business if the taxpayer does it continuously and regularly with the intent of making a profit… A single taxpayer can have more than one trade or business.”3 Also, taxpayers may have multiple activities that nevertheless are only a single trade or business. HHC stated that if 280E applies to its marijuana sales, the business should be entitled to deduct expenses for any separate, non-trafficking trades or businesses. HHC argued it had four activities. The IRS argued HHC operated only as one trade or business, whose business was “trafficking in a controlled substance” and therefore subject to 280E. The Tax Court analyzed the sales volume, floor space, and employee time spent on the four different operations and ultimately determined that HHC’s primary operation was selling marijuana and marijuana-related products and its other activities were “neither economically separate nor substantially different.” 3) Cost of Goods Sold All taxpayers, even drug traffickers pay tax only on gross income, which is defined as gross receipts less the cost of goods sold. This means HHC is not limited to owing taxes based on its gross receipts. However, the definition of cost of goods sold came into question. The Code has three sections that address cost of goods sold – Section 263, Section 263A and Section 471. Since there are multiple sections the question becomes which section applies to HHC? The IRS argued the applicability of Section 471, enacted in 1954 which was in place when Congress enacted Section 280E in 1982. Section 471 has separate regulations for resellers and producers. The regulations state “resellers” use as their cost of goods sold, the price they pay for inventory plus any “transportation or other necessary charges incurred in acquiring possession of the goods.” The regulations for “producers” are more complex. Producers must include in cost of goods sold both direct and indirect costs of creating their inventory. The regulations state to inventory: “cost of raw materials”, “expenditures for direct labor” and “indirect production costs incident to and necessary for production of the particular article”. HHC argued that limiting its cost of goods sold to “only the actual cost used to purchase inventory” violates the Sixteenth Amendment and that “section 263A represented the most accurate tax-accounting method for calculating cost of goods sold.” The Constitution does limit Congress to taxing only gross income,4 and HHC argued that not letting marijuana dispensaries use 263A forces them to pay tax on more than their gross income.” The Tax Court ultimately ruled “Section 263A capitalization rules don’t apply to drug traffickers. Unlike most businesses, drug traffickers can’t capitalize indirect expenses beyond what’s listed in the section 471 regulations. Section 263A expressly prohibits capitalizing expenses that wouldn’t otherwise be deductible and drug traffickers don’t get deductions. Because federal law labels HHC a drug trafficker, it must calculate its cost of goods sold according to Section 471”. Next the Tax Court had to determine whether HHC is a “producer” or a “reseller” in accordance with Section 471 since there are different rules for producers versus resellers as far as how to calculate its cost of goods sold. The IRS argued that under Section 471 “production” means “manufacturing” while the Tax Court added that “producers” retain title to the items throughout the production process. The question became did HHC own what its growers grew? HHC argued that “it exercised a high degree of control over the growers it purchased marijuana from. HHC only purchased marijuana from its members and even then, only if the members used HHC clones (which they purchase or received for free), took HHC growing class, followed HHC’s best practices and met HHC quality control standards”. The IRS stated HHC “didn’t create the clones, maintain tight control over them, order specific quantities, prevent sales to third parties or take possession of everything produced. HHC bought clones from nurseries and either sold them to growers with no strings attached or gave clones to growers expecting that they’d sell the bud back to HHC. Nothing prevented either type of grower from selling to another collective and [HHC’s owner] Steve DeAngelo thought it would be futile to try to use the courts to stop them. HHC had complete discretion over whether to purchase what bud the growers brought in, paid growers only if it purchased their bud, and at times rejected the ‘vast majority’ of its growers’ bud. And HHC thought growers could do whatever they wanted with the rejected bud.” The Tax Court ruled “HHC merely sold or gave members clones that it had purchased from nurseries and bought back bud if and when it wanted. In between these two steps it had no ownership interest in the marijuana plants. HHC is therefore a reseller for the purposes of Section 471 and must adjust for its cost of goods sold according to Section 1.471-3(b).” This is the most restrictive calculation regarding the costs of goods sold and thereby the lowest calculation for the cost of goods sold. Thus, HHC could only include its purchase of the products and related transportation costs. Conclusion The Patients Mutual Assistance Collective Corp. case further denies ordinary and necessary business expenses for entities they operate in the cannabis industry. The case also defines the criteria to determine cost of goods sold. If you have questions about the case, its impact on the cannabis industry, or any related matter, please contact a member of the HBK Cannabis Industry group at Cannabis Industry Inquiry. Our team will walk you through the options and help you decide what strategies may be best for your cannabis-based business.   Footnotes
  1. PATIENTS MUTUAL ASSISTANCE COLLECTIVE CORPORATION d.b.a.HARBORSIDE HEALTH CENTER, Petitioner v. COMMISSIONER OF INTERNAL REVENUE, Respondent, Docket Nos. 29212-11, 30851-12, 14776-14, Filed November 29, 2018.
  2. PATIENTS MUTUAL ASSISTANCE COLLECTIVE CORPORATION d.b.a.HARBORSIDE HEALTH CENTER v. COMMISSIONER, 2018, p25.
  3. Ibid, p37.
  4. Gross income is defined as gross receipts minus direct costs.

Speak to one of our professionals about your organizational needs

"*" indicates required fields

hbkcpa.com needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.